French Orthopedics: A Market in Transition
Long the most innovative market in Europe, French orthopedics has been hit by reimbursement squeezes and marketing and regulatory reforms. In the process, this once-insular market is being forced to become more cosmopolitan. But the biggest challenge may come as biological approaches to therapy challenge traditional implants.
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.